Hochmair Maximilian, Kiiskinen Urpo, D'yachkova Yulia, Puri Tarun, Wang Xuwen, Wolowacz Sorrel, Vickers Adrian, Nadal Ernest
Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Eli Lilly and Company, Indianapolis, IN, USA.
Future Oncol. 2025 Jun;21(15):1867-1878. doi: 10.1080/14796694.2025.2508132. Epub 2025 Jun 3.
Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.
MATERIALS & METHODS: Efficacy and safety were compared using matching-adjusted indirect comparison.
Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.
Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.
塞尔帕替尼和普拉替尼已被批准用于治疗RET重排的非小细胞肺癌。
采用匹配调整间接比较法比较疗效和安全性。
塞尔帕替尼和普拉替尼的中位无进展生存期（PFS）分别为22.1个月和13.3个月（HR = 0.67；95%CI，0.53 - 0.85）。客观缓解率分别为64.5%和65.8%，疾病控制率分别为92.1%和90.4%。塞尔帕替尼的中位总生存期未达到，普拉替尼为43.9个月（HR = 0.81；95%CI，0.60 - 1.09）。39.3%和62.6%的患者报告了≥3级治疗相关不良事件（TRAEs），因TRAEs停药的患者分别为3.6%和10.0%。
结果相似；然而，塞尔帕替尼显著延长了PFS，且≥3级TRAEs较少。
